Imagion Biosystems Limited previously advised that the Renounceable Rights Issue announced on 25 March 2020 (“Offer”) has closed oversubscribed and raised $2.05 million. To accommodate some of the excess demand, the Company had agreed to raise an additional $0.96 million on the same terms as the Offer (“Follow-On Placement”).
Chairman’s Address to Shareholders and Q&A Session at 2023 Annual General Meeting
May 25, 2023
Imagion Biosystems’ Chairman’s address to shareholders at the 2023 Annual General Meeting. PDF of the 2023 AGM Presentation Deck Watch the AGM 2023 Q&A Session